Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Total Non-Current Liabilities (2021 - 2023)

Arcturus Therapeutics Holdings' Total Non-Current Liabilities history spans 3 years, with the latest figure at $150.4 million for Q4 2023.

  • For Q4 2023, Total Non-Current Liabilities fell 15.16% year-over-year to $150.4 million; the TTM value through Dec 2023 reached $150.4 million, down 15.16%, while the annual FY2023 figure was $150.4 million, 15.16% down from the prior year.
  • Total Non-Current Liabilities reached $150.4 million in Q4 2023 per ARCT's latest filing, down from $176.6 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $177.3 million in Q4 2022 to a low of $128.5 million in Q1 2021.
  • Average Total Non-Current Liabilities over 3 years is $153.0 million, with a median of $144.3 million recorded in 2022.
  • Peak YoY movement for Total Non-Current Liabilities: dropped 17.09% in 2022, then grew 22.41% in 2023.
  • A 3-year view of Total Non-Current Liabilities shows it stood at $174.0 million in 2021, then rose by 1.87% to $177.3 million in 2022, then dropped by 15.16% to $150.4 million in 2023.
  • Per Business Quant, the three most recent readings for ARCT's Total Non-Current Liabilities are $150.4 million (Q4 2023), $176.6 million (Q3 2023), and $144.2 million (Q2 2023).